Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00492336 · ClinicalTrials.gov registry record · Phase 4
Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 84
- Enrollment target
NCT00492336 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 84 participants.
The verdict
NCT00492336, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a study of a new medication for the treatment of cognitive impairments (thinking difficulties) and negative symptoms in people with schizophrenia. The new medication is rasagiline. Rasagiline is a drug which has been approved by the Food and Drug Administration for the treatment of Parkinson's disease. It is used to treat cognitive problems.
Interventions
- DRUG Placebo
- DRUG rasagiline (Pharmacodynamics)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2007-01 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00492336
The ClinicalTrials.gov registry entry for NCT00492336 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00492336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00492336 about?
NCT00492336 is a clinical study titled "Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia". This is a study of a new medication for the treatment of cognitive impairments (thinking difficulties) and negative symptoms in people with schizophrenia. The new medication is rasagiline. Rasagiline is a drug which has been approved by the Food and Drug Administration for the treatment of Parkinson...
What is the current status of trial NCT00492336?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 84 participants. The study started on 2007-01. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00492336?
The interventions under investigation include: Placebo (DRUG), rasagiline (Pharmacodynamics) (DRUG).
Who is sponsoring clinical trial NCT00492336?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.